All News

Top news of the day from across the health care landscape.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

As growing levels of antibiotic resistance continues to concern health care professionals, the results of a recent study suggest that giving daily probiotic supplements to children can reduce their likelihood of requiring antibiotics.

Pamrevlumab is advancing towards phase 3 clinical development for idiopathic pulmonary fibrosis early next year.

Some researchers propose that vasomotor symptoms may signal physiologic processes that might be associated with other related systemic health diagnoses.

Presenters at the International Pharmaceutical Federation (FIP) World Congress in Glasgow, Scotland identified the current landscape of Hepatitis C, how pharmacists can position themselves to aid in point of care testing, and ways to better educate patients and providers.

Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with hairy cell leukemia.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat diabetic retinopathy.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Officials with the FDA have approved AstraZeneca’s moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least 2 prior systemic therapies.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application of aflibercept (EYLEA Injection) to treat diabetic retinopathy.

A recent survey evaluated the baseline knowledge of licensed pharmacists with regard to common pet toxins.

Tocilizumab’s newest formulation offers an additional administration option for children diagnosed systemic juvenile idiopathic arthritis, a rare and debilitating disease.

Azathioprine, a drug used to treat a variety of conditions, may contribute to skin cancer development.

More than 65% of patients with Kaposi’s sarcoma in a small cohort had partial or complete remission when treated with immune checkpoint inhibitors.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

B cells activate T cells in the blood to cause inflammation and brain lesions in patients with multiple sclerosis.

One in 5 test results showed potentially dangerous concurrent use of opioids and benzodiazepines in 2017.

A study examined whether silymarin, is an active extract of milk thistle, has a therapeutic effect and can improve hepatic enzyme measures.

A new study examining HIV in people who inject drugs found interventions increased use of antiretroviral medication.

With Hurricane Florence about to strike, pharmacies must take extra steps to maintain services for patients in need of lifesaving medications.

Having an emergency plan helps pharmacists, pharmacies, and patients protect themselves and their medications, during a disaster event and in the aftermath.

Azathioprine is known to cause increased photosensitivity to UVA light, but the new findings indicate an association between the drug and the mutational signature found in cases of cutaneous squamous cell carcinoma.